Analyst Profile

Followed by 32 followers
.
Gil Blum

Gil Blum

Needham
Wall Street Analyst
#8,068 out of 8,160 Wall Street Analysts
#23,976 out of 24,427 experts

Success Rate

27%
53 out of 197 transactions made a profit

Average Return

-23.40%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Gil Blum's trades since 2022 and holding each position for 1 Year would result in 26.90% of your transactions generating a profit, with an average return of -23.4% per rating.

Stock Rating Distribution

261Ratings
91.57% Buy
8.43% Hold
0.00% Sell
Distribution of Gil Blum's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market
United KingdomUK Market

Best Rating

Stock:
CTI BioPharma Corp.
(CTIC)
Rating:Buy
Date:Dec 01, 2021 - Dec 01, 2022
Return:+267.00%
The most profitable rating made by Gil Blum

Gil Blum's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
Athenex
Jan 21, 2022
Hold
Assigned
3Ratings
0.00%
Genocea Biosciences
Apr 06, 2022
Buy
Reiterated
$6.00
(545354.55% Upside)
5Ratings
0%
-83.56%
Athersys
Jun 03, 2022
Hold
Assigned
6Ratings
0%
-67.44%
Aeglea Biotherapeutics
Aug 25, 2022
Hold
Assigned
10Ratings
0%
-74.13%
I-MAB
Sep 12, 2022
Buy
Reiterated
$33.00
(789.49% Upside)
13Ratings
0%
-70.58%
Selecta Biosciences
Oct 17, 2022
Buy
Reiterated
$5.00
(283.14% Upside)
8Ratings
43%
-4.41%
Avrobio
Oct 20, 2022
Buy
Reiterated
$6.00
(581.97% Upside)
13Ratings
18%
-50.77%
Mereo Biopharma Group Plc
Oct 31, 2022
Buy
Reiterated
$5.00
(502.26% Upside)
12Ratings
25%
-12.05%
G1 Therapeutics
Nov 02, 2022
Buy
Reiterated
$32.00
(412.41% Upside)
8Ratings
13%
-32.29%
Crispr Therapeutics AG
Nov 02, 2022
Buy
Reiterated
$122.00
(133.00% Upside)
11Ratings
22%
-18.53%
List of latest recommendations made by Gil Blum. Click to expand and see Gil Blum's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >